Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTO1 | P78417 | 2/20 | 0.44 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2760659 | 0.86 | GSTO1 (0.44) | GSTO1GLALMNACCR2CA12 | |
| SCHEMBL6196958 | 0.85 | ADRA1D (0.47) | PTGES2CCR2CMA1PTGS2CA12 | |
| SCHEMBL29707969 | 0.83 | PTGES2 (0.43) | GSTO1PTGES2LMNACA12CA1 | |
| SCHEMBL15881385 | 0.83 | PTGES2 (0.43) | GSTO1PTGES2LMNACA12CA1 | |
| SCHEMBL1015882 | 0.81 | GSTO1 (0.44) | GSTO1GLALMNACCR2ALDH1A1 | |
| SCHEMBL939720 | 0.81 | PTGES2 (0.55) | PTGES2CA12CA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL28301073 | 0.81 | PTGES2 (0.42) | GSTO1PTGES2LMNACA12CA1 | |
| SCHEMBL48740 | 0.81 | GSTO1 (0.41) | GSTO1GLALMNACCR2CYP3A4 | |
| SCHEMBL19277188 | 0.81 | GSTO1 (0.68) | GSTO1LMNAALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL2760682 | 0.80 | GSTO1 (0.43) | GSTO1GLALMNACCR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200207769-A1 | DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN-LA ROCHE INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-10633384-B2 | Diazaspirocycloalkane and azaspirocycloalkane | HOFFMANN-LA ROCHE INC. (US) | 2020-04-28 | — | — | US | disclosed |
| CN-104364239-B | Diaza spiro cycloalkane and azaspiro alkane | 霍夫曼-拉罗奇有限公司 | 2017-08-25 | — | — | CN | disclosed |
| US-20170029425-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN-LA ROCHE INC. (US) | 2017-02-02 | — | — | US | disclosed |
| EP-2861566-B1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN LA ROCHE (CH) | 2016-12-21 | — | — | EP | disclosed |
| US-9493486-B2 | Diazaspirocycloalkane and azaspirocycloalkane | HOFFMANN-LA ROCHES INC. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-2861566-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | F. Hoffmann-La Roche AG (CH) | 2015-04-22 | — | — | EP | disclosed |
| US-20150099734-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN-LA ROCHE INC. (US) | 2015-04-09 | — | — | US | disclosed |
| EP-2271624-B9 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-11-12 | — | — | EP | disclosed |
| EP-2271624-B1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-05-21 | — | — | EP | disclosed |
| US-20110124876-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110039846-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-17 | — | — | US | disclosed |
| US-20110034464-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2271624-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20090270393-A1 | Iminopyridine Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009131245-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | WO | disclosed |
| EP-1091933-B1 | SUBSTITUTED BETA-DIKETONES AND THEIR USE | ORION CORP (FI) | 2003-11-26 | — | — | EP | disclosed |
| EP-1091933-A1 | SUBSTITUTED $g(b)-DIKETONES AND THEIR USE | ORION CORPORATION (FI) | 2001-04-18 | — | — | EP | disclosed |
| US-6201027-B1 | NONSTEROIDAL ANTIINFLAMMATORY DRUG FOR PROPHYLAXIS AND TREATMENT OF RESPIRATORY SYSTEM DISORDERS, I.E. ASTHMA, IN STEROID-RESISTANT MAMMALS | ORION CORPORATION (FI) | 2001-03-13 | — | — | US | disclosed |
| WO-2000001667-A1 | SUBSTITUTED β-DIKETONES AND THEIR USE | ORION CORPORATION (FI) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207769-A1 | DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | ENPP2, DAPK1, DAPK2 | GSTO1 1262/4885PTGES2 4720/4885GLA 162/4885 |
| US-20110034464-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | GSTO1 3565/4885PTGES2 1359/4885GLA 3458/4885 |
| US-20170029425-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | ENPP2, DAPK1, DAPK2 | GSTO1 1814/4885PTGES2 4781/4885GLA 213/4885 |
| US-20110124876-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | GSTO1 3565/4885PTGES2 1359/4885GLA 3458/4885 |
| US-20110039846-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | GSTO1 3565/4885PTGES2 1359/4885GLA 3458/4885 |
| US-10633384-B2 | Diazaspirocycloalkane and azaspirocycloalkane | ENPP2, DAPK1, DAPK2 | GSTO1 1262/4885PTGES2 4720/4885GLA 162/4885 |
| US-20150099734-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | DAPK2, DAPK1, IDH3A | GSTO1 1931/4885PTGES2 3981/4885GLA 2040/4885 |
| US-20090270393-A1 | Iminopyridine Derivatives and Use Thereof | ADRA1D, ADRB1, ADRB2 | GSTO1 3565/4885PTGES2 1359/4885GLA 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.